Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.
Mary Maluccio, MD, MPH, FACS
Articles by Mary Maluccio, MD, MPH, FACS
Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.
A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.
Latest Updated Articles
Efficacy, Safety of 212Pb-DOTAMTATE in PRRT-Naive Patients With GEP-NETsPublished: October 29th 2025 | Updated:
212Pb-DOTAMTATE Advances to Phase 3 Trial in GEP-NETs, Continues Phase 2 Follow-UpPublished: October 31st 2025 | Updated: